pre-IPO PHARMA

Maze Therapeutics to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference

Tags:  


SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced that management will participate in a fireside chat at the 2023 Cantor Fitzgerald Global Healthcare Conference on Tuesday, September 26, 2023, from 12:25 to 12:55 p.m. ET.


A live webcast of the presentation will be available in the news and press section of the company's website at www.mazetx.com. The webcast will be archived for 90 days following the presentation.



About Maze Therapeutics

Maze Therapeutics is a biopharmaceutical company harnessing the power of human genetics to transform the lives of patients. The Company is committed to developing breakthrough precision medicines for common diseases with large unmet medical needs. Maze has developed Maze CompassTM, a proprietary, purpose-built platform to leverage genetic variation and integrate the critical step of variant functionalization into each stage of therapeutic development. Utilizing Maze CompassTM, the Company's strategy is to develop its therapies independently, in collaboration with major pharmaceutical companies, and through company formation. For more information, please visit mazetx.com, or follow us on LinkedIn and Twitter.


Contacts

Jillian Connell, Maze Therapeutics jconnell@mazetx.com (650) 850-5080


Media: Dan Budwick, 1AB dan@1abmedia.com

Jillian Connell, Maze Therapeutics jconnell@mazetx.com (650) 850-5080


Media: Dan Budwick, 1AB dan@1abmedia.com